Nonconvulsive status epilepticus due to ifosfamide

Annals of Pharmacotherapy

Volumn 40, Issue 2, 2006, Pages 332-335

  Kilickap, Saadettin ^a   Cakar, Mustafa ^a   Onal, Ibrahim K ^a   Tufan, Abdurrahman ^a   Akoglu, Hadim ^a   Aksoy, Sercan ^a   Erman, Mustafa ^a   Tekuzman, Gulten ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Ifosfamide; Levetiracetam; Nonconvulsive status epilepticus

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DIAZEPAM; DOXORUBICIN; ETIRACETAM; ETOPOSIDE; FLUOROURACIL; GABAPENTIN; IDARUBICIN; IFOSFAMIDE; LORAZEPAM; MESNA; PREDNISOLONE; TRAMADOL; VINCRISTINE;

ADULT; ARTICLE; B CELL LYMPHOMA; BRAIN DISEASE; CASE REPORT; CLINICAL FEATURE; COMA; CONFUSION; CONSCIOUSNESS DISORDER; DETERIORATION; DISEASE SEVERITY; DOSE RESPONSE; EPILEPTIC STATE; FEMALE; HUMAN; LETHARGY; MAINTENANCE THERAPY; NEUROTOXICITY; NONCONVULSIVE EPILEPTIC STATE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SPEECH DISORDER; UTERINE CERVIX CANCER;

ANTICONVULSANTS; ANTINEOPLASTIC AGENTS, ALKYLATING; DIAZEPAM; FEMALE; HUMANS; IFOSFAMIDE; MIDDLE AGED; NEOPLASMS; PIRACETAM; STATUS EPILEPTICUS;

EID: 33144486084     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G363     Document Type: Article

References (29)

1. Patel SR, Forman AD, Benjamin RS. High-dose ifosfamide-induced exacerbation of peripheral neuropathy. J Natl Cancer Inst 1994;86:305-6.
2. Manegold C, Drings P, Pawinski A, et al. Oral ifosfamide/mesna versus intravenous ifosfamide/mesna in non-small cell lung cancer: a randomized phase II trial of the EORTC Lung Cancer Cooperative Group. Ann Oncol 1996;7:637-9.
3. Weiss RB. Miscellaneous toxicities. In: De Vita VT, Hellman S, Rosenberg SA, eds. Cancer principles and practice of oncology. 6th ed. Philadelphia: Lippincott Williams & Wilkins, 2001:2964-76.
4. Spira AI, Ettinger DS. The use of chemotherapy in soft-tissue sarcomas. Oncologist 2002;7:348-59.
5. Zelenetz AD, Hamlin P, Kewalramani T, Yahalom J, Nimer S, Moskowitz CH. Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggresive non-Hodgkin's lymphoma. Ann Oncol 2003;14(supple 1):i5-10.
6. Hagermeister FB. The role of ifosfamide in the treatment of lymphomas. Leuk Lymphoma 1999;34(5-6):433-41.
7. Meanwell CA, Blake AE, Blackledge G, et al. Encephalopathy associated with ifosfamide/mesna. Lancet 1985;1:406-7.
8. Pratt CB, Green AA, Horowitz ME, et al. Central nervous system toxicity following ifosfamide treatment for children with malignant solid tumors. J Clin Oncol 1986;4:1253-61.
9. Sood C, O'Brien PJ. 2-Chloroacetaldehyde-induced cerebral glutathione depletion and neurotoxicity. Br J Cancer 1996;27(suppl):S287-93.
10. Kupfer A, Aeschlimann C, Cerny T. Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy. Eur J Clin Pharmacol 1996;50:249-52.
11. Rieger C, Fiegl M, Tischer J, Ostermann H, Schiel X. Incidence and severity of ifosfamide-induced encephalopathy. Anticancer Drugs 2004;15:347-50.
12. Nicolao P, Giometto B. Neurological toxicity of ifosfamide. Oncology 2003;65(suppl 2):11-6.
13. Anderson NR, Tandon DS. Ifosfamide extrapyramidal neurotoxicity. Cancer 1991;68:72-5.
14. Meanwell CA, Blake AE, Kelly KA, Honigsberger L, Blackledge G. Prediction of ifosfamide/mesna associated encephalopathy. Eur J Cancer Clin Oncol 1986;7:815-9.
15. Tuxen MK, Hansen SW. Neurotoxicity secondary to antineoplastic drugs. Cancer Treat Rev 1994;20:191-214.
16. Adverse Drug Reactions Advisory Committee. Tramadol-four years' experience. Aust Adverse Drug React Bull 2003;22:2.
17. Shneker BF, Fountain NB. Assessment of acute morbidity and mortality in nonconvulsive status epilepticus. Neurology 2003;61:1066-73.
18. Wengs WJ, Talwar D, Bernard J. Ifosfamide-induced nonconvulsive status epilepticus. Arch Neurol 1993;50:1104-5.
19. Bhardwaj A, Badesha PS. Ifosfamide-induced nonconvulsive status epilepticus. Ann Pharmacother 1995;29:1237-9.
20. Primavera A, Audenino D, Cocito L. Ifosfamide encephalopathy and nonconvulsive status epilepticus. Can J Neurol Sci 2002;29:180-3.
21. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
22. Husain AM, Horn GJ, Jacobson MP. Non-convulsive status epilepticus: usefulness of clinical features in selecting patients for urgent EEG. J Neurol Neurosurg Psychiatry 2003;74:189-91.
23. Pelgrims J, De Vos F, Van den Brande J, Schrijvers D, Prove A, Vermorken JB. Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. Br J Cancer 2000;82:291-4.
24. Kasper B, Harter C, Meissner J, et al. Prophylactic treatment of known ifosfamide-induced encephalopathy for chemotherapy with high-dose ifosfamide? Support Care Cancer 2004;12:205-7.
25. Turner AR, Duong CD, Good DJ. Methylene blue for the treatment and prophylaxis of ifosfamide-induced encephalopathy. Clin Oncol (R Coll Radiol) 2003;15:435-9.
26. Kupfer A, Aeschlimann C, Wermuth B, Cerny T. Prophylaxis and reversal of ifosfamide encephalopathy with methylene-blue. Lancet 1994;343:763-4.
27. Simonian NA, Gilliam FG, Chiappa KH. Ifosfamide causes a diazepam-sensitive encephalopathy. Neurology 1993;43:2700-2.
28. Ben-Menachem E. Levetiracetam: treatment in epilepsy. Expert Opin Pharmacother 2003;4:2079-88.
29. Mazarati AM, Baldwin R, Klitgaard H, Matagne A, Wasterlain CG. Anticonvulsant effects of levetiracetam and levetiracetam-diazepam combinations in experimental status epilepticus. Epilepsy Res 2004;58:167-74.